Summary
Global Markets Direct’s, ‘Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H1 2016’, provides in depth analysis on Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted pipeline therapeutics.
The report provides comprehensive information on the Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
- The report reviews Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Angion Biomedica Corp.
Merck & Co., Inc.
Novartis AG
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Overview 6
Therapeutics Development 7
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Stage of Development 7
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Therapy Area 8
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Indication 9
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Companies 12
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Universities/Institutes 14
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Companies Involved in Therapeutics Development 20
Angion Biomedica Corp. 20
Merck & Co., Inc. 21
Novartis AG 22
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Drug Profiles 23
ANG-3586 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
CFG-920 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
osilodrostat phosphate - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecule to Inhibit CYP11B2 for Cardiovascular Disease - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules to Inhibit CYP17 and CYP11B2 for Prostate Cancer - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Inhibit CYP19 and CYP11B2 for Cardiovascular Diseases - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Dormant Projects 31
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Discontinued Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34
List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by Angion Biomedica Corp., H1 2016 20
Pipeline by Merck & Co., Inc., H1 2016 21
Pipeline by Novartis AG, H1 2016 22
Dormant Projects, H1 2016 31
Discontinued Products, H1 2016 32
List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Actions, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 19
